ALNY
HealthcareAlnylam Pharmaceuticals, Inc. · Biotechnology · $40B
What is Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals is a biopharmaceutical company pioneering RNA interference (RNAi) therapeutics — a gene-silencing approach that targets disease at the genetic level. It is headquartered in Cambridge, Massachusetts.
Alnylam discovers, develops, and commercializes medicines that use RNAi technology to silence genes responsible for serious diseases. Revenue comes from marketed products and strategic collaborations with larger pharmaceutical partners. Its focus areas span genetic diseases, cardio-metabolic conditions, liver-related infections, and CNS/ocular disorders.
Alnylam was founded in 2004 and is based in Cambridge, US.
- ONPATTRO (patisiran) — hereditary transthyretin amyloidosis treatment
- GIVLAARI — acute hepatic porphyria therapy
- OXLUMO (lumasiran) — primary hyperoxaluria type 1 treatment
- Pipeline candidates targeting hypertension, hemophilia, and NASH
Is ALNY a Good Stock to Buy?
UQS Score rates ALNY as Good overall.
The Growth pillar stands out as the clearest strength, reflecting Alnylam's expanding commercial portfolio and deep pipeline. The Risk pillar also rates favorably, suggesting the company's financial and operational risk profile is relatively managed for a clinical-stage-to-commercial biopharmaceutical.
Valuation is rated Elevated, meaning the market may already be pricing in considerable future success. Quality and Moat both sit at Neutral, indicating room for improvement as the business matures.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ALNY pay dividends?
No — Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.
Alnylam does not currently pay a dividend. Like many growth-stage biopharmaceutical companies, it reinvests available capital into research, clinical development, and commercializing its RNAi pipeline rather than returning cash to shareholders.
When does ALNY report earnings?
Alnylam Pharmaceuticals reports earnings on a quarterly cadence, typical for US-listed equities.
Results in recent periods have reflected the company's transition toward a multi-product commercial stage, with growing product revenues partially offset by continued investment in pipeline development. Progress on key pipeline candidates has been a recurring theme in quarterly updates.
For the most recent quarter's results, visit Alnylam Pharmaceuticals' investor relations page directly.
ALNY Price History
+117.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Alnylam Pharmaceuticals, Inc.?
Based on Alnylam Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Alnylam Pharmaceuticals do?
Alnylam develops medicines based on RNA interference, a technology that silences specific genes involved in disease. Its approved products treat rare genetic and metabolic conditions, and its pipeline targets a broader range of serious diseases including hypertension and hemophilia.
Does ALNY pay dividends?
No, ALNY does not pay a dividend. The company reinvests capital into its RNAi research platform and clinical pipeline, which is common for biopharmaceutical companies still scaling their commercial operations.
When does ALNY report earnings?
Alnylam reports on a standard quarterly schedule. The company does not pre-announce specific dates far in advance, so check Alnylam's investor relations page for the most current earnings calendar.
Is ALNY a good stock to buy?
UQS Score rates ALNY as Good overall. The Growth pillar is a clear strength, while Valuation is rated Elevated and both Quality and Moat are Neutral. Whether it fits your portfolio depends on your risk tolerance and investment horizon. Pro members can view the full pillar breakdown.
Is ALNY overvalued?
ALNY's Valuation pillar is rated Elevated within the UQS framework, suggesting the current price reflects high expectations for future growth. Investors should weigh this against the company's strong Growth profile and pipeline potential.
What is ALNY's market cap bracket?
ALNY is classified as a large-cap stock, placing it among the more established companies in the biopharmaceutical space despite still being in a growth-oriented phase of its commercial development.
Is ALNY a long-term quality indicator?
From a UQS perspective, ALNY's long-term quality profile is mixed. Growth is rated Strong and Risk is Good, but Quality and Moat are both Neutral — meaning the business has not yet demonstrated the durable competitive advantages or financial consistency typically associated with the highest long-term quality scores.
What sector does ALNY belong to?
Alnylam Pharmaceuticals operates in the Healthcare sector, specifically within biopharmaceuticals. It focuses on a specialized technology platform — RNA interference — that differentiates it from traditional small-molecule drug developers.
Unlock Full ALNY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for ALNY
- ✓Access detailed financial metrics behind the Quality and Moat ratings
- ✓Compare ALNY side-by-side with competitors like ARGX, INSM, and RVMD
- ✓Screen the full Healthcare sector by pillar strength
Pro Analysis
ALNY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 67.1 | 70.8 | 53.0 | 100.0 | 72.3 | 35.8 | 0.0 |
| May 22, 2026 | 67.1 | 70.7 | 53.0 | 100.0 | 72.3 | 35.6 | 0.0 |
| May 21, 2026 | 67.1 | 70.8 | 53.0 | 100.0 | 72.3 | 35.7 | -0.1 |
| May 20, 2026 | 67.2 | 70.8 | 53.0 | 100.0 | 72.3 | 35.9 | 0.0 |
| May 19, 2026 | 67.2 | 70.9 | 53.0 | 100.0 | 72.3 | 36.2 | 0.0 |
| May 16, 2026 | 67.2 | 70.9 | 53.0 | 100.0 | 72.3 | 36.1 | 0.0 |
| May 15, 2026 | 67.2 | 70.8 | 53.0 | 100.0 | 72.3 | 35.9 | 0.0 |
| May 14, 2026 | 67.2 | 70.8 | 53.0 | 100.0 | 72.3 | 36.0 | 0.0 |
| May 13, 2026 | 67.2 | 70.9 | 53.0 | 100.0 | 72.3 | 35.9 | -0.1 |
| May 12, 2026 | 67.3 | 70.9 | 53.0 | 100.0 | 72.3 | 36.2 | +0.1 |
ALNY — Pillar Breakdown
Quality
— 70.8/100 (25%)Alnylam Pharmaceuticals, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Alnylam Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 72.3/100 (15%)Alnylam Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 35.8/100 (15%)Alnylam Pharmaceuticals, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 53/100 (25%)Alnylam Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ALNY.
Score Composition
Financial Data
More Stock Analysis
How is the ALNY UQS Score Calculated?
The UQS (Unified Quality Score) for Alnylam Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Alnylam Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Alnylam Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.